Fig. 3From: Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader-Willi syndrome: a randomized, active-controlled triala Mean change in lean body mass at week 52 from baseline b Mean change in percent body fat at week 52 from baseline. * P-value was obtained from Paired t-test. ‡ P-value was obtained from Wilcoxon’s signed rank test. CI, confidence interval; SE, standard errorBack to article page